Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Clinical Presentation and Treatment Responses in IgM AL Amyloidosis, a Series of 106 Patients

John Mark Sloan, MD, Moussa Sissoko, MD, David C Seldin, MD PhD, Brian Sworder, MD, Kennneth Angelino, MD, Mike Broce, John L Berk, MD, Vaishali Sanchorawala, MD

Blood (2014) 124 (21): 4750.

https://doi.org/10.1182/blood.V124.21.4750.4750

Published: 2014

Journal Articles

Pomalidomide and Dexamethasone in Patients with Relapsed AL (Light Chain) Amyloidosis: Results of a Phase 1 Study

Vaishali Sanchorawala, MD, Anthony C Shelton, RN, Stephen Lo, John Mark Sloan, MD, David C Seldin, MD PhD

Blood (2014) 124 (21): 3463.

https://doi.org/10.1182/blood.V124.21.3463.3463

Published: 2014

Journal Articles

Clinical Presentation and Treatment Responses In IgM-Related AL Amyloidosis

Moussa Sissoko, MD, Vaishali Sanchorawala, MD, David C Seldin, MD, PhD, Brian Sworder, MD, John L Berk, MD, John Mark Sloan, MD

Blood (2013) 122 (21): 1991.

https://doi.org/10.1182/blood.V122.21.1991.1991

Published: 2013

Journal Articles

Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center

Vaishali Sanchorawala, MD, Gheorghe Doros, Karen Quillen, MD, MPH, John Mark Sloan, MD, Anthony C Shelton, RN, Dina Brauneis, ANP, Kathleen T Finn, ANP, David C Seldin, MD, PhD

Blood (2013) 122 (21): 3328.

https://doi.org/10.1182/blood.V122.21.3328.3328

Published: 2013

Journal Articles

Risk of Second Primary Malignancies in Patients with AL Amyloidosis Treated with Lenalidomide

Vaishali Sanchorawala, MD, Anthony C Shelton, RN, Gheorghe Doros, PhD, David C Seldin, MD, PhD

Blood (2012) 120 (21): 1873.

https://doi.org/10.1182/blood.V120.21.1873.1873

Published: 2012

Journal Articles

Treatment of AL Amyloidosis with Two Cycles of Induction Therapy with Bortezomib and Dexamethasone Followed by Bortezomib-High Dose Melphalan Conditioning and Autologous Stem Cell Transplantation

Vaishali Sanchorawala, MD, Anthony C Shelton, RN, Dina Brauneis, ANP, Karen Quillen, MD, MPH, Nancy T Andrea, MD, John Mark Sloan, MD, David C Seldin, MD, PhD

Blood (2012) 120 (21): 2019.

https://doi.org/10.1182/blood.V120.21.2019.2019

Published: 2012

Journal Articles

Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Final Results of A Phase II Trial

Divya Nair, MD, Vaishali Sanchorawala, MD, Anthony C Shelton, RN, Salli A Fennessey, Kathleen T Finn, ANP, Martha Skinner, MD, Jerome B. Zeldis, MD, PhD, David C Seldin, MD, PhD

Blood (2012) 120 (21): 4084.

https://doi.org/10.1182/blood.V120.21.4084.4084

Published: 2012

Journal Articles

Modified High-Dose Melphalan and Autologous Stem Cell Transplantation (mHDM/SCT) In the Treatment of AL Amyloidosis (AL) and/or High-Risk Myeloma (hM): Analysis of SWOG Trial S0115

Vaishali Sanchorawala, MD, Antje Hoering, PhD, David C Seldin, MD, PhD, Kathleen T Finn, ANP, Salli A Fennessey, Bassam I Mattar, MD, Hana F Safah, MD, Leona Holmberg, MD, PhD, Robert M. Dean, MD, Robert Z. Orlowski, MD, PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 2004.

https://doi.org/10.1182/blood.V118.21.2004.2004

Published: 2011

Journal Articles

Infectious Complications In Patients with AL (Immunoglobulin Light Chain) Amyloidosis Undergoing Treatment with High-Dose Melphalan and Autologous Stem-Cell Transplantation (HDM/SCT)

Sarah Taimur, MD, Claudia Nader, MD, Christine Lloyd-Travaglini, David C Seldin, MD, PhD, Vaishali Sanchorawala, MD

Blood (2011) 118 (21): 2041.

https://doi.org/10.1182/blood.V118.21.2041.2041

Published: 2011

Journal Articles

High-Dose Melphalan and Stem Cell Transplantation for Patients with AL Amyloidosis and Cardiac Involvement

Saulius Girnius, M.D., David C Seldin, MD, PhD, Karen Quillen, MD, MPH, Nancy T Andrea, MD, John Mark Sloan, MD, John L Berk, MD, Frederick L Ruberg, MD, Hans Meier-Ewert, MD, Vaishali Sanchorawala, MD

Blood (2011) 118 (21): 2043.

https://doi.org/10.1182/blood.V118.21.2043.2043

Published: 2011

Journal Articles

Doxycycline Reduces Fibril Formation in a Transgenic Mouse Model of AL Amyloidosis

David C Seldin, MD, PhD, Jennifer Ward, PhD, Ruiyi Ren, MSc, Gianluca Toraldo, PhD, Pamela T SooHoo, BA, Jian Guan, BS, Carl O'Hara, Ravi Jasuja, PhD, Vickery Trinkaus-Randall, PhD, Ronglih Liao, PhD, Lawreen H Connors, PhD

Blood (2011) 118 (21): 1837.

https://doi.org/10.1182/blood.V118.21.1837.1837

Published: 2011

Journal Articles

Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients

M. Teresa Cibeira, MD, PhD, Vaishali Sanchorawala, MD, David C Seldin, MD, PhD, Karen Quillen, MD, MPH, Nancy Andrea, MD, J. Mark Sloan, MD, Kathleen T Finn, ANP, John L Berk, MD, Gheorghe Doros, PhD, Joan Blade, Martha Skinner, MD

Blood (2010) 116 (21): 2394.

https://doi.org/10.1182/blood.V116.21.2394.2394

Published: 2010

Journal Articles

Macroglossia – Not Always AL Amyloidosis

Andrew J Cowan, MD, Martha Skinner, MD, J. Mark Sloan, MD, John L Berk, MD, Carl J O'Hara, MD, David C Seldin, MD, PhD, Vaishali Sanchorawala, MD

Blood (2010) 116 (21): 5007.

https://doi.org/10.1182/blood.V116.21.5007.5007

Published: 2010

Journal Articles

Dysregulation of miRNAs In AL Amyloidosis

Liangping Weng, MD, Brain Spencer, Pam Soo Hoo, Lawreen Connors, Carl O'Hara, David C Seldin, MD, PhD

Blood (2010) 116 (21): 4648.

https://doi.org/10.1182/blood.V116.21.4648.4648

Published: 2010

Journal Articles

Increases In B-Type Natriuretic Peptide (BNP) During Treatment with Lenalidomide In AL Amyloidosis

Umit Tapan, MD, David C Seldin, MD, PhD, Kathleen T Finn, ANP, Salli Fennessey, CRA, Anthony C Shelton, RN, Jerome B. Zeldis, MD, PhD, Vaishali Sanchorawala, MD

Blood (2010) 116 (21): 3021.

https://doi.org/10.1182/blood.V116.21.3021.3021

Published: 2010

Journal Articles

Lenalidomide Treatment In Patients with AL Amyloidosis Associated End-Stage Renal Disease and Dialysis

Vaishali Sanchorawala, MD, Kathleen T Finn, ANP, Salli Fennessey, CRA, Anthony C Shelton, RN, Jerome B. Zeldis, MD, PhD, David C Seldin, MD, PhD

Blood (2010) 116 (21): 3022.

https://doi.org/10.1182/blood.V116.21.3022.3022

Published: 2010

Journal Articles

Oral Cyclic Melphalan and Dexamethasone in the Treatment of Patients with AL Amyloidosis; Ineligible for High-Dose Melphalan and Stem Cell Transplantation.

Vaishali Sanchorawala, MD, David C. Seldin, MD, PhD, John Mark Sloan, MD, John L. Berk, MD, Martha Skinner

Blood (2009) 114 (22): 1883.

https://doi.org/10.1182/blood.V114.22.1883.1883

Published: 2009

Journal Articles

Second Autologous Peripheral Blood Stem Cell Transplantation with High Dose Melphalan (HDM/SCT) in Patients Relapsing After An Initial Course of HDM/SCT for the Treatment of AL Amyloidosis.

Karen Quillen, MD, David C. Seldin, MD, PhD, Kathleen T. Finn, RN, ANP, AOCN, Vaishali Sanchorawala, MD

Blood (2009) 114 (22): 2318.

https://doi.org/10.1182/blood.V114.22.2318.2318

Published: 2009

Journal Articles

Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis.

Saulius Girnius, MD, Frank Tsai, MD, David C. Seldin, MD, PhD, Karen Quillen, MD, Lisa Yanarella, NP, Kathleen T. Finn, NP, Nancy T. Andrea, MD, John Mark Sloan, MD, Martha Skinner, MD, Vaishali Sanchorawala, MD

Blood (2009) 114 (22): 4352.

https://doi.org/10.1182/blood.V114.22.4352.4352

Published: 2009

Journal Articles

Bortezomib and High Dose Melphalan Followed by Autologous Stem Cell Transplantation (BortHDM/SCT) for the Treatment of AL Amyloidosis: Results of a Feasibility Study.

Vaishali Sanchorawala, MD, Lisa Yanarella, NP, Karen Quillen, MD, John Mark Sloan, MD, Nancy T. Andrea, MD, Kathleen T. Finn, NP, David C. Seldin, MD, PhD

Blood (2009) 114 (22): 4353.

https://doi.org/10.1182/blood.V114.22.4353.4353

Published: 2009

NARROW

Clinical Presentation and Treatment Responses in IgM AL Amyloidosis, a Series of 106 Patients

Pomalidomide and Dexamethasone in Patients with Relapsed AL (Light Chain) Amyloidosis: Results of a Phase 1 Study

Clinical Presentation and Treatment Responses In IgM-Related AL Amyloidosis

Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center

Risk of Second Primary Malignancies in Patients with AL Amyloidosis Treated with Lenalidomide

Treatment of AL Amyloidosis with Two Cycles of Induction Therapy with Bortezomib and Dexamethasone Followed by Bortezomib-High Dose Melphalan Conditioning and Autologous Stem Cell Transplantation

Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Final Results of A Phase II Trial

Modified High-Dose Melphalan and Autologous Stem Cell Transplantation (mHDM/SCT) In the Treatment of AL Amyloidosis (AL) and/or High-Risk Myeloma (hM): Analysis of SWOG Trial S0115

Infectious Complications In Patients with AL (Immunoglobulin Light Chain) Amyloidosis Undergoing Treatment with High-Dose Melphalan and Autologous Stem-Cell Transplantation (HDM/SCT)

High-Dose Melphalan and Stem Cell Transplantation for Patients with AL Amyloidosis and Cardiac Involvement

Doxycycline Reduces Fibril Formation in a Transgenic Mouse Model of AL Amyloidosis

Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients

Macroglossia – Not Always AL Amyloidosis

Dysregulation of miRNAs In AL Amyloidosis

Increases In B-Type Natriuretic Peptide (BNP) During Treatment with Lenalidomide In AL Amyloidosis

Lenalidomide Treatment In Patients with AL Amyloidosis Associated End-Stage Renal Disease and Dialysis

Oral Cyclic Melphalan and Dexamethasone in the Treatment of Patients with AL Amyloidosis; Ineligible for High-Dose Melphalan and Stem Cell Transplantation.

Second Autologous Peripheral Blood Stem Cell Transplantation with High Dose Melphalan (HDM/SCT) in Patients Relapsing After An Initial Course of HDM/SCT for the Treatment of AL Amyloidosis.

Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis.

Bortezomib and High Dose Melphalan Followed by Autologous Stem Cell Transplantation (BortHDM/SCT) for the Treatment of AL Amyloidosis: Results of a Feasibility Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only